60,000 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Bought by Diadema Partners LP

Diadema Partners LP acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 60,000 shares of the company's stock, valued at approximately $3,322,000. Tarsus Pharmaceuticals accounts for 1.4% of Diadema Partners LP's portfolio, making the stock its 15th biggest position. Diadema Partners LP owned approximately 0.16% of Tarsus Pharmaceuticals at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of TARS. Barclays PLC boosted its holdings in Tarsus Pharmaceuticals by 345.9% during the third quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after buying an additional 76,538 shares in the last quarter. Geode Capital Management LLC increased its stake in Tarsus Pharmaceuticals by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 835,790 shares of the company's stock worth $27,494,000 after purchasing an additional 62,555 shares in the last quarter. Franklin Resources Inc. increased its stake in Tarsus Pharmaceuticals by 9.3% in the 3rd quarter. Franklin Resources Inc. now owns 12,164 shares of the company's stock worth $444,000 after purchasing an additional 1,033 shares in the last quarter. Exome Asset Management LLC acquired a new stake in Tarsus Pharmaceuticals during the 3rd quarter worth about $1,500,000. Finally, Lord Abbett & CO. LLC lifted its stake in Tarsus Pharmaceuticals by 28.4% during the third quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company's stock valued at $19,565,000 after buying an additional 131,636 shares in the last quarter. Institutional investors own 90.01% of the company's stock.

Insider Buying and Selling

In related news, General Counsel Bryan Wahl sold 3,341 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the transaction, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dianne C. Whitfield sold 2,315 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the sale, the insider now directly owns 50,751 shares of the company's stock, valued at approximately $2,349,263.79. This trade represents a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,542 shares of company stock worth $1,581,173 in the last 90 days. Corporate insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Price Performance

Shares of Tarsus Pharmaceuticals stock traded up $0.03 during midday trading on Friday, hitting $50.00. 754,503 shares of the company were exchanged, compared to its average volume of 689,977. The firm has a 50 day simple moving average of $47.60 and a 200-day simple moving average of $48.34. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The firm has a market cap of $1.92 billion, a P/E ratio of -13.12 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on TARS shares. HC Wainwright reiterated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Jefferies Financial Group increased their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Barclays lowered their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.